The MeCo Score™ is the first and only clinically validated biomarker test to help with therapy selection for patients with early-stage breast cancer who have a higher risk of relapse (1,2,3) and may benefit from FDA-approved antifibrotic therapy (3)*.

A powerful new tool for personalized treatment

Partnerships & Collaborations

Funding

Awards & Affiliations

References

[1] Watson, A.W. et al. (2021). Cell Reports. 29;35(13):109293. doi: 10.1016/j.celrep.2021.109293

[2] Data on file with Cleveland Clinic and MeCo Diagnostics Holdings, Inc.

[3] Quintela-Fandino, M. et al. (2024). Clinical Cancer Research. doi: 10.1158/1078-0432.CCR-24-1518

Note: the prescribing information for the FDA-approved therapy may not include a an associated biomarker, and the proposed indication of use for the MeCo Score is subject to change.

*The MeCo Score (TM) assay is for Investigational Use Only

and is not cleared or approved by the Food and Drug Administration.